대시보드포트폴리오관심 목록커뮤니티발견스크리너
NOT FOR DISTRIBUTION

Herbalife Ltd.

NYSE:HLF 주식 리포트

시가총액: US$1.3b

  • 회사 개요
    • 가치 평가
    • 미래 성장
    • 과거 실적
    • 재무 건전성
    • 배당
  • 경영진
  • 지분
  • 기타 정보
  • 주식 커뮤니티

Herbalife 향후 성장

Future 기준 점검 3/6

Herbalife은 연간 수입과 매출이 각각 37.2%와 2.6% 증가할 것으로 예상되고 EPS는 연간 36.1%만큼 증가할 것으로 예상됩니다.

핵심 정보

37.2%

이익 성장률

36.11%

EPS 성장률

Personal Products 이익 성장27.4%
매출 성장률2.6%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트01 Sep 2026

최근 향후 성장 업데이트

분석 기사 • Aug 08

Herbalife Ltd. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Herbalife Ltd. ( NYSE:HLF ) came out with its second-quarter results last week, and we wanted to see how the business...

Recent updates

Seeking Alpha • Aug 17

Herbalife Ltd.: The Share Price Is Discounting Terminal Decline

Summary Herbalife Ltd. is rated a 'risky' Buy, with shares trading at a steep discount and the market pricing in an overly pessimistic perpetual decline. HLF posted four consecutive quarters of YoY net sales growth, driven mainly by a one-off India GST cut, while other regions showed mixed or declining volume trends. Strategic repositioning toward personalized nutrition and deleveraging efforts are underway, with net leverage reduced to 2.2x and $45M in annual cash interest savings unlocked. Despite risks from GLP-1 adoption, growth concentration, leverage, and regulatory exposure, the current price offers potential upside versus a base case fair value near $24. Read the full article on Seeking Alpha
분석 기사 • Aug 08

Herbalife Ltd. Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts

Herbalife Ltd. ( NYSE:HLF ) came out with its second-quarter results last week, and we wanted to see how the business...
User avatar
내러티브 업데이트 • Aug 07

HLF: 2026 Guidance Execution And Margin Expansion Will Support Share Recovery

Analysts have trimmed their price target on Herbalife to $17 from $21, reflecting updated views on fair value, discount rate, revenue growth, profit margins and future P/E assumptions. What’s in the News for Herbalife Herbalife raised its full year 2026 net sales guidance to a range of 2.5% to 5.5% year over year, compared with its previous range of 1.5% to 5.5% year over year.
User avatar
내러티브 업데이트 • Jun 18

HLF: Execution On 2026 Guidance And Margins Will Drive Stock Rebound

Analysts have lifted their price target on Herbalife to about $18.33 from $17.50, citing updated assumptions around discount rates, expected revenue growth, profit margins, and future P/E multiples reflected in recent research. Analyst Commentary Recent research on Herbalife highlights a mix of optimism around execution and valuation, alongside ongoing caution about the company’s ability to sustain and convert growth assumptions into consistent earnings.
User avatar
내러티브 업데이트 • Jun 03

HLF: Refinancing And Margin Improvement Will Support Turnaround Despite Weak EBITDA Guidance

Narrative update on Herbalife Analysts have raised their price target on Herbalife by $2, citing research that points to updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Bullish analysts raising their price target by US$2 are signaling a more constructive view on how Herbalife’s valuation lines up with its fundamentals.
분석 기사 • May 19

Investors Can Find Comfort In Herbalife's (NYSE:HLF) Earnings Quality

Investors were disappointed with the weak earnings posted by Herbalife Ltd. ( NYSE:HLF ). However, our analysis...
User avatar
내러티브 업데이트 • May 05

HLF: Mixed 2026 Guidance And Execution Outlook Will Shape Turnaround Prospects

Herbalife's analyst price target has been revised higher to $17.50 from $16.50, with analysts pointing to updated fair value assumptions and recent target increases at firms such as Citi, BofA and Mizuho following Q4 results and 2026 guidance. Analyst Commentary Recent research updates show a mix of optimism and caution around Herbalife, with price targets moving in different directions as analysts react to Q4 results, 2026 guidance and updated assumptions around execution and valuation.
User avatar
내러티브 업데이트 • Apr 20

HLF: 2026 Guidance And Margin Recovery Will Drive Turnaround Momentum

Analysts lifted their price targets for Herbalife by as much as $4, with some pointing to Q4 results that were largely in line, fresh 2026 guidance, and what they view as stronger recent momentum as key factors behind the adjustment. Analyst Commentary Bullish analysts are highlighting recent price target increases on Herbalife as a sign of improving confidence in the story, especially after Q4 results that were described as largely in line and supported by new 2026 guidance.
User avatar
내러티브 업데이트 • Apr 06

HLF: Turnaround Momentum And Q1 2026 Outlook Will Support Margin Recovery

Herbalife's updated analyst price target has moved from $14.00 to $16.50 as analysts factor in recent target increases, slightly higher projected revenue growth and margins, and a modestly lower discount rate, alongside updated views on valuation multiples. Analyst Commentary Recent research views on Herbalife show a mix of optimism about a potential turnaround and caution about the broader sector and the company’s fundamentals.
User avatar
내러티브 업데이트 • Mar 23

HLF: 2026 Turnaround Ambitions Will Face Ongoing Competitive And Fundamental Pressures

Herbalife's analyst price target has shifted toward $9.00, with recent research citing Q4 results viewed as solid by some firms, new 2026 guidance, and mixed views on valuation and competitive pressures. Some analysts also commented that regulatory concerns in the U.S. are considered resolved and the business model more sustainable.
User avatar
내러티브 업데이트 • Mar 09

HLF: 2026 Turnaround Hopes Will Confront Persistent Competitive And Fundamental Risks

The analyst price target for Herbalife has been raised by $1 to $9. Analysts point to largely in line Q4 results, new 2026 guidance, and a mix of Buy, Neutral, and Underperform views that reflect both perceived momentum and ongoing concerns around competition, fundamentals, and valuation.
User avatar
내러티브 업데이트 • Feb 23

HLF: Turnaround Will Be Driven By 2026 Guidance And Margin Recovery

Narrative Update: Herbalife The updated analyst fair value estimate for Herbalife has moved from $11 to $25, a shift analysts link to refreshed price targets in the $9 to $21 range, stronger Q4 commentary, improved margin assumptions, and a lower discount rate despite mixed views on long term growth and valuation risks. Analyst Commentary Recent Street research on Herbalife reflects a mix of views, but several bullish analysts have been willing to raise price targets or upgrade their stance following recent updates from the company.
User avatar
내러티브 업데이트 • Feb 08

HLF: Turnaround Hopes Under New Leadership Will Confront Compressed Sector Multiples

Narrative Update: Herbalife Analyst Price Target Move The blended analyst price target for Herbalife has moved higher, with recent increases such as Mizuho's lift to $13 and Maxim's initiation at $20. Analysts point to an ongoing turnaround, progress under new leadership, and a healthier long term profile for Herbalife's business model, while also noting continuing concerns about competition and broader macro uncertainty.
User avatar
내러티브 업데이트 • Jan 25

HLF: Recovery Story Under New Leadership Will Face Compressed Sector Multiples

Narrative Update on Herbalife The analyst price target for Herbalife has been revised higher to reflect an updated fair value of $8.00, a lower discount rate of 10.02%, and adjustments to revenue growth, profit margin, and future P/E assumptions, as analysts factor in recent target hikes, Buy initiations, and views of a continuing recovery path under new leadership. Analyst Commentary Recent Street research on Herbalife reflects a mix of optimism about a potential recovery and caution around execution and valuation risks.
분석 기사 • Jan 22

Herbalife Ltd. (NYSE:HLF) Shares Fly 27% But Investors Aren't Buying For Growth

Herbalife Ltd. ( NYSE:HLF ) shares have continued their recent momentum with a 27% gain in the last month alone. The...
User avatar
내러티브 업데이트 • Jan 11

HLF: Turnaround And Margin Recovery Under New Leadership Will Face Valuation Constraints

The analyst price target on Herbalife in our model has moved from US$12 to US$14, as analysts point to a recovery path supported by a healthier profit margin outlook, a slightly lower discount rate, and recent research highlighting ongoing business model improvements despite tempered revenue growth expectations and cautious sector valuations. Analyst Commentary Recent research on Herbalife reflects a mix of optimism about the company’s turnaround efforts and caution about broader sector and macro headwinds.
User avatar
내러티브 업데이트 • Dec 25

HLF: Recovery Path Under New Leadership Will Likely Deliver Disappointing Multiple Expansion

Analysts have modestly raised their fair value estimate for Herbalife from approximately $9.67 to $12.00 per share, citing a lower perceived risk profile, steady growth and margin assumptions, and a more constructive view on future earnings multiples as fundamentals continue on a recovery path under new leadership. Analyst Commentary Analyst sentiment around Herbalife is gradually improving as execution under new leadership gains traction and forward growth expectations firm up, though views on the pace and durability of the recovery remain mixed.
User avatar
내러티브 업데이트 • Dec 11

HLF: Recovery Path Under New Leadership Will Likely Prove Overpriced

Analysts have modestly raised their price target on Herbalife to $11 from $10, citing a gradually lower perceived risk profile, steady long term growth and margin assumptions, and growing confidence that the company is on a recovery path under new leadership, with a potential return to volume growth by fiscal 2026. Analyst Commentary Bullish analysts point to the recent rating upgrade and price target increase as evidence that sentiment around Herbalife is gradually improving, with expectations that operational execution will support a more favorable risk and reward profile over the next several years.
User avatar
내러티브 업데이트 • Nov 27

HLF: Uncertainty Around CEO Transition Will Challenge Near-Term Momentum

Herbalife’s analyst price target has been raised to $11 from $10, as analysts point to recovering fundamentals and the company’s strategic leadership changes as promising signs for future growth. Analyst Commentary Analysts have recently weighed in on Herbalife, offering a mix of optimism about its improving fundamentals and some caution about ongoing risks.
분석 기사 • Nov 13

We Think That There Are Some Issues For Herbalife (NYSE:HLF) Beyond Its Promising Earnings

The market for Herbalife Ltd.'s ( NYSE:HLF ) stock was strong after it released a healthy earnings report last week...
분석 기사 • Oct 29

The Market Doesn't Like What It Sees From Herbalife Ltd.'s (NYSE:HLF) Earnings Yet

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
분석 기사 • Sep 26

At US$8.75, Is Herbalife Ltd. (NYSE:HLF) Worth Looking At Closely?

Herbalife Ltd. ( NYSE:HLF ), might not be a large cap stock, but it saw a decent share price growth of 11% on the NYSE...
분석 기사 • Jul 24

A Look At The Intrinsic Value Of Herbalife Ltd. (NYSE:HLF)

Key Insights The projected fair value for Herbalife is US$9.20 based on 2 Stage Free Cash Flow to Equity Herbalife's...
분석 기사 • Jun 25

There's No Escaping Herbalife Ltd.'s (NYSE:HLF) Muted Earnings Despite A 26% Share Price Rise

Those holding Herbalife Ltd. ( NYSE:HLF ) shares would be relieved that the share price has rebounded 26% in the last...
분석 기사 • May 28

Herbalife (NYSE:HLF) Hasn't Managed To Accelerate Its Returns

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
분석 기사 • May 08

Herbalife's (NYSE:HLF) Earnings Offer More Than Meets The Eye

Herbalife Ltd.'s ( NYSE:HLF ) solid earnings announcement recently didn't do much to the stock price. We did some...
분석 기사 • Mar 13

Herbalife Ltd.'s (NYSE:HLF) Share Price Boosted 63% But Its Business Prospects Need A Lift Too

Herbalife Ltd. ( NYSE:HLF ) shares have had a really impressive month, gaining 63% after a shaky period beforehand. But...
Seeking Alpha • Feb 24

Herbalife: The Battleground Stock Is Showing Some Turnaround Potential

Summary Herbalife still operates in 95 countries using a direct selling and MLM model with six million independent distributors. Currently, HLF is facing declining sales volumes, which have been partly offset by price increases. However, it remains uncertain how sustainable this is in the long run. Post-FTC settlement, I think HLF has “sanitized” its business model, even though it has indeed made it more challenging to grow its MLM business. The good news is its focus. They have a mixed regional performance, in particular with China struggling while Asia Pacific stabilizes. Additionally, its recruitment and sales leaders numbers have been encouraging in Q4 and 2024. Based on EV/EBITDA metrics, HLF is undeniably still priced at a steep discount. However, at this point, I believe the risk-reward equation is more favorable for the bulls. Hence, I rate it a speculative “Buy” for the short term. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:HLF - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20285,558373N/AN/A2
12/31/20275,390306N/AN/A3
12/31/20265,259165N/AN/A3
6/30/20265,201164322384N/A
3/31/20265,133240374447N/A
12/31/20255,038228253333N/A
9/30/20254,962321217305N/A
6/30/20254,929325171265N/A
3/31/20254,951280164272N/A
12/31/20244,993254163285N/A
9/30/20245,00187180312N/A
6/30/20245,04282156292N/A
3/31/20245,075137188325N/A
12/31/20235,062142223358N/A
9/30/20235,028186173315N/A
6/30/20235,042226156305N/A
3/31/20235,121252123268N/A
12/31/20225,204321196353N/A
9/30/20225,342305224384N/A
6/30/20225,477340244403N/A
3/31/20225,637398321481N/A
12/31/20215,803447309460N/A
9/30/20215,896483347487N/A
6/30/20215,986504400531N/A
3/31/20215,781474476597N/A
12/31/20205,542373517629N/A
9/30/20205,351356571673N/A
6/30/20205,074299624728N/A
3/31/20204,967260N/A561N/A
12/31/20194,877311N/A458N/A
9/30/20194,843303N/A440N/A
6/30/20194,842293N/A418N/A
3/31/20194,887311N/A531N/A
12/31/20184,892297N/A648N/A
9/30/20184,799184N/A696N/A
6/30/20184,641168N/A659N/A
3/31/20184,503211N/A572N/A
12/31/20174,428214N/A591N/A
9/30/20174,379377N/A522N/A
6/30/20174,416410N/A276N/A
3/31/20174,471249N/A402N/A
12/31/20164,488260N/A367N/A
9/30/20164,542245N/A385N/A
6/30/20164,523251N/A638N/A
3/31/20164,483357N/A609N/A
12/31/20154,469339N/A629N/A
9/30/20154,504358N/A555N/A

애널리스트 향후 성장 전망

수입 대 저축률: HLF 의 연간 예상 수익 증가율(37.2%)이 saving rate(3.7%)보다 높습니다.

수익 vs 시장: HLF 의 연간 수익(37.2%)이 US 시장(17.2%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: HLF 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: HLF 의 수익(연간 2.6%)이 US 시장(연간 13.4%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: HLF 의 수익(연간 2.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.


주당순이익 성장 예측


향후 자기자본이익률

미래 ROE: HLF의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.


성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/09/14 19:09
종가2026/09/11 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
  • SEC 양식 10-K
  • SEC 양식 10-Q
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
  • 분석가 리서치 보고서
  • Blue Matrix
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
  • ICE 시장 데이터
  • SEC 양식 S-1
지분 구조10년
  • 주요 주주
  • 내부자 거래
  • SEC 양식 4
  • SEC 양식 13D
경영진10년
  • 리더십 팀
  • 이사회
  • SEC 양식 10-K
  • SEC 양식 DEF 14A
주요 개발10년
  • 회사 공시
  • SEC 양식 8-K

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Herbalife Ltd.는 14명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
John StaszakArgus Research Company
Meredith AdlerBarclays
Brian WangBarclays

어디서든 더 나은 투자 결정을 내리세요

스캔하여 다운로드
App Store 열기Google Play 열기
Chrome 웹 스토어
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
데이터 소스 보기
시장
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
투자 아이디어
  • 저평가 기업
  • 고배당 우량주
  • 임원 매수
  • 원자력 에너지
  • 자율주행차
  • 인공지능
  • 암호화폐 및 블록체인
  • 사이버보안
  • 더 많은 아이디어
주식 커뮤니티
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
기능 및 도구
  • 포트폴리오 추적기
  • 주식 스크리너 & 알림
  • 내러티브 및 적정 가치
  • 배당 계산기
뉴스 및 탐색
  • 최신 주식 뉴스
  • 글로벌 시장 인사이트
  • 더 폭스홀
  • 투자 아이디어
  • 커뮤니티 스토리
  • 새로운 소식
Simply Wall St
  • 플랜 및 가격
  • 광고
  • 회사 소개
  • 문의하기
  • 채용
  • 도움말 센터
  • 주식 투자 학습
  • 제휴 프로그램
  • 비즈니스 & 엔터프라이즈
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • 이용 약관
  • 개인정보처리방침
  • AI 약관
  • 금융 서비스 가이드